CA2514252A1 - A therapeutic composition for the treatment of hiv-1 and hiv-2 - Google Patents
A therapeutic composition for the treatment of hiv-1 and hiv-2 Download PDFInfo
- Publication number
- CA2514252A1 CA2514252A1 CA002514252A CA2514252A CA2514252A1 CA 2514252 A1 CA2514252 A1 CA 2514252A1 CA 002514252 A CA002514252 A CA 002514252A CA 2514252 A CA2514252 A CA 2514252A CA 2514252 A1 CA2514252 A1 CA 2514252A1
- Authority
- CA
- Canada
- Prior art keywords
- amount
- present
- desferrin
- allocryptopine
- chromium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A pharmaceutical mixture and a method of its production of a therapeutic composition for blocking the HIV-1 and HIV-2 virus replication in the CD4+
cells of the human immune system in all stages of that viral infection, and in AIDS for the treatment of HIV in a patient in need of such treatment.
cells of the human immune system in all stages of that viral infection, and in AIDS for the treatment of HIV in a patient in need of such treatment.
Description
A THERAPEUTIC COMPOSITION
Applicant claims the benefit of following prior filed co-pending U.S. Patent Application, Serial No. 10/353,483, filed 29 January X003.
BACKGROUND OF THE INVENTION
A pharmaceutical mixture for blocking the HIV-1 and/or HIV-2 virus 1 o replication in the CI~4+ cells of the human immune system in all stages of that viral infection, and in AIDS, also the method of production of the pharmaceutical mixture for blocking the HIV-1 and HIV-2 virus replication in the CI~4~+ cells of the human immune system in all stages of that viral infection, and in AIDS.
Hereinafter it should be understood that the terms "HIV treatment" and 15 "treatment of HIV in a patient in need of such treatment" mean treating a patient with HIV-1 and/or HIV-2. Additionally, the teen "blocking HIV virus replication" means blocking HIV-1 andfor HIV-2 virus replication. Further the term "HIV virus" refers to the HIV-1 andlor HIV-2 virus. Still further, the term "HIV infection" refers to HIV-1 and/or HIV-2 infection.
Applicant claims the benefit of following prior filed co-pending U.S. Patent Application, Serial No. 10/353,483, filed 29 January X003.
BACKGROUND OF THE INVENTION
A pharmaceutical mixture for blocking the HIV-1 and/or HIV-2 virus 1 o replication in the CI~4+ cells of the human immune system in all stages of that viral infection, and in AIDS, also the method of production of the pharmaceutical mixture for blocking the HIV-1 and HIV-2 virus replication in the CI~4~+ cells of the human immune system in all stages of that viral infection, and in AIDS.
Hereinafter it should be understood that the terms "HIV treatment" and 15 "treatment of HIV in a patient in need of such treatment" mean treating a patient with HIV-1 and/or HIV-2. Additionally, the teen "blocking HIV virus replication" means blocking HIV-1 andfor HIV-2 virus replication. Further the term "HIV virus" refers to the HIV-1 andlor HIV-2 virus. Still further, the term "HIV infection" refers to HIV-1 and/or HIV-2 infection.
2 o The subject of the invention is a pharmaceutical mixture for blocking the HIV-1 and HIV-2 virus replication in the CI~4+ cells of the human immune system in all stages of that viral infection, and in AIDS, also the method of production of the pharmaceutical mixture for blocking the HIV-1 and HIV-2 virus replication in the CD4+ cclls of the human immune system in all stages of that viral infection, z s and in All7S.
The invented mixture has a particular application in treatment of the Acquired Immunodeficiency Syndrome, or AIDS.
Synopsis of the Description The subj ect of the invention is a pharmaceutical mixture for blocking the HIV-1 and HIV-2 virus replication in the GD4+ cells of the human immune system in that viral infection, and in All~S contains previously known carriers and/or auxiliary substances, as well as active substances, and it is characterized by the presence of at least 10 chemical substances as active substances, among them, allocryptopine, present in the amount from 1.0 mg to 10.0 mg; nimodipine, present to in the amount from 20.0 mg to 100.0 mg; potassium iodide, present in the amount from 120.0 mg to 560.0 mg; potassium iodate, present in the amount from 30.0 mg to 140.0 mg; inulina, present in the amount from 125.0 mg to 375.0 mg; silver, present in the amount from 0.10 mg to 0.50 mg; zinc, present in the amount from 10.0 mg to 20.0 mg; chromium, present in the amount from 0.05 mg to 0.20 mg;
orotic acid, present in the amount from 150.0 mg to 500.0 mg; desferrin, present in the amount from 100.0 mg to 300.0 mg Summary A pharmaceutical mixture and a method of its production of a therapeutic 2o composition for blocking the HIV-1 and HIV-2 virus replication in the CI~4~+ cells of the human immune system in all stages of that viral infection, and in .~IL2S for the treatment of HIV in a patient in need of such treatment, the therapeutic composition comprising of pharmaceutically effective amounts of allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid and desferrin. In one embodiment of the invention, the pharmaceutical mixture and method further comprises pharmaceutically effective amounts of taraxasterol and B-sitosterol.
Detailed Description of the Invention The invention pertains also to the method of production of the pharmaceutical mixture for blocking the HIV-1 and HIV-2 virus replication in the C1~4+ cells of the human immune system in all stages of that viral infection, and in to AIDS, characterized by mixing, in the room temperature, of allocryptopine, in the amount from 1.0 mg to 10.0 mg; nimodipine, in the amount from 20.0 mg to 100.0 mg; potassium iodide, in the amount from 120.0 mg to 560.0 mg; potassium iodate, in the amount from. 30.0 mg to 140.0 mg; inuline, in the amount from 125.0 mg to 375.0 mg; silver, in the amount from 0.10 mg to 0.50 mg; zinc, in the amount from is 10.0 mg to 20.0 mg; chromium, in the amount from 0.05 mg to 0.20 mg; orotic acid, in the amount from 150.0 mg to 500.0 mg; desferrin, in the amount from 100.0 mg to 300.0 mg, until a mix approximating uniform substance is produced, subsequently pressed into tablets, and can also have a form of coated tablets, or can be shaped into a wafer, a suppository, effervescent powder, gel, or colloid solution;
2 0 or made into suspension, syrup, salt soluble in body fluids, or liquid for intramuscular or I~ injections, also in ampules.
In the existing publications pertaining to treatment regimens for patients with a diagnosed HIV infection, or with the Acquired Imrnunodeficiency Syndrome (AIDS), there has been no description of any medications/ pharmaceutical preparations for blocking the HIV-1 and HIV-2 virus replication in the CD4+
cells of the human immune system based on the reasoning adopted here.
The premiss underlying the invention discussed here is the reasoning that the basis for the HIV- I and HIV-2 virus replication in the CD4+ cells of the human immune system is the exeitono-excimeric correlation between the HIV- I and HIV-2 viruses and the CD4 cell of the human immune system.
The effect of the adoption of that reasoning is as follows: the initiation of the therapy aimed at treatment of the HIV-1 and HIV-2 viral infections, and AIDS, to is reduced to delivering substances completely blocking the mechanism causing the HIV-1 and HIV-2 replication to the patient's body.
The following substances proved to be helpful in that task: allocryptopine, an alkaloid found in the Chelidonium maius plant, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid and desferrin.
Other 15 substances found to be helpful in this task were taraxasterol and B-sitosterol.
It is known that: allocryptopine is a nucleotide phosphodiesterase blocker, nimodipine is a calcium channel blocker, potassium iodide when combined with potassium iodate in the acidic environment, produces iodic free radicals, inuline is a polysaccharide which is not decomposed in the body9 silver, zinc, and chromium ~ o are elements playing a role in the enzymatic processes, - desferrin chelates ferric ions, - ~r~tic acid a the precursor of the nucleotide compounds.
However, the substances listed above have never appeared nor been applied together, and in particular they have not been used together in the therapeutic application such as those described in this invention.
The goal of the invention is supplying the pharmaceutical mixture for blocking the HIV-1 and HIV-2 virus replication in the CD4+ cells of the human immune system.
The invention provides that the pharmaceutical mixture for blocking the HIV-1 and HIV2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS, contains previously known carriers and/or auxiliary substances, as well as active substances, and it is characterized by the presence of at least 10 chemical substances as active substances, among them:
to - allocryptopine is present in the amount from 1.0 mg to 10.0 mg, - nimodipine is present in the amount from 20.0 mg to 100.0 mg, - potassium iodide is present in the amount from 120.0 mg to 560.0 mg, - potassium iodate is present in the amount from 30.0 mg to 140.0 mg, - inuline is present in the amount from 125.0 mg to 375.0 mg, 15 - silver is present in the amount from 0.10 mg to 0.50 mg, - zinc is present in the amount from 10.0 mg to 20.0 mg, -- chromium is present in the amount from 0.05 mg to 0.20 mg, - orotic acid is present in the amount from 150.0 mg to 500.0 mg, -desferrin is present in the amount from 100.0 mg to 300.0 mg ao It is beneficial v~hen:
- allocryptopine content is 10.0 mg, - and nimodipine content is 100.0 mg, - and potassium iodide content is 560.0 mg, - and potassium iodate content is 140.0 mg, - and inuline content is 375.0 mg, - and silver content is 0.50 mg, - and zinc content is 20.0 mg, - and chromium content is 0.20 mg, and orotic acid content is 500.0 mg, - and desferrin content is 300.0 mg.
It is beneficial when:
- allocryptopine content is 4.50 mg, - and nimodipine content is 60.0 mg, - and potassium iodide content is 340.0 mg, i5 - and potassium iodate content is X5.0 mg, - and inuline content is 250.0 mg, - and silver content is 0.30 mg, - and zinc content is 15.0 mg, - and chromium content is 0.125 mg, - and orotic acid content is 325.0 mg, - and desferrin content is 200.0 mg.
It is beneficial when:
_7_ - allocryptopine content is 4.50 mg, - and nimodipine content is 60.0 mg, - and potassium iodide content is 340.0 mg, - and potassium iodate content is 85.0 mg, - and inuline content is 250.0 mg, - and silver content is 0.30 mg, - and zinc content is 15.0 mg, - and chromium content is 0.125 mg, - and orotic acid content is 325.0 mg, to - and desferrin content is 200.0 mg, - and taraxasterol content is 350 mg, - and B-sitosterol content is 400 mg, It is beneficial when:
- allocryptopine content is 1.0 mg, - and nimodipine content is 20.0 mg, - and potassium iodide content is 120.0 mg, - and potassium iodate content is 30.0 mg, - and inulinc content is 125.0 mg, ~ o - and silver content is 0.10 mg, - arid zinc content is 10.0 mg, - and chromium content is 0.05 mg, - and orotic acid content is 250.0 mg, _g_ - and desferrin content is 100.0 mg, - and taraxasterol content is 250 mg, - and B-sitosterol content is 300 mg It is beneficial when:
- allocryptopine content is 1.0 mg, - and nimodipine content is 20.0 mg, - and potassium iodide content is 120.0 mg, - and potassium iodate content is 30.0 mg, to - and muline content is 125.0 mg, - and silver content is 0.10 mg, - and zinc content is 10.0 mg, - and chromium content is 0.05 mg, - and orotic acid content is 250.0 mg, - and desferrin content is 100.0 mg.
It is beneficial when the weight ratio of allocryptopine to nimodipine to potassium iodide to potassium iodate to inuline to silver to zinc to chromium to orotic acid to desferrin is generally maintained as 1:20:120:30:125:0.1:10:0.05:250:100.
~ o It is beneficial when the mixture of the ingredients has a form of a tablet, or coated tablet, or wafer, oi° suppository, or effervescent powder°, or gel, or colloid solution.
It is beneficial when the mixture of the ingredients has a form of suspension, or syrup, or salt soluble in body fluids, or liquids for intramuscular or IV injections.
The production of the pharmaceutical mixture for blocking the HIV-1 and HIV-2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS, is characterized by mixing, in the room temperature, the following ingredients: - - allocryptopine in the amount from 1.0 ~, mg to 10.0 mg, - nimodipme in the amount from 20.0 mg to 100.0 mg, - potassium iodide in the amount from 120.0 mg to 560.0 mg, so - potassium iodatc in the amount from 30.0 mg to 140.0 mg, - incline in the amount from 125.0 mg to 375.0 mg, - silver in the amount from 0.10 mg to 0.50 mg, - zinc in the amount from 10.0 mg to 20.0 mg, - chromium in the amount from 0.05 mg to 0.20 mg, - orotic acid in the amount from 150.0 mg to 500.0 mg, -desferrin in the amount from 100.0 mg to 300.0 mg, until homogeneous mixture is created.
It is beneficial when:
2 0 - alloc~yptopine content is 10.0 mg, - and nimodipinc content is 100.0 mg, - and potassium iodide content is 560.0 mg, - and potassium iodate content is 140.0 mg, - and inuline content is 375.0 mg, - and silver content is 0.50 mg, - and zinc content is 20.0 mg, - and chromium content is 0.20 mg, - and orotic acid content is 500.0 mg, - and desferrin content is 300.0 mg.
It is beneficial when:
- allocryptopine content is 4.50 mg, - and nimodipine content is 60.0 mg, to - and potassium iodide content is 340.0 mg, - and potassium iodate content is 85.0 mg, - and inuline content is 250.0 mg, - and silver content is 0.30 mg, - and zinc content is 15.0 mg, - and chromium content is 0.125 mg, - and orotic acid content is 325.0 mg, - and desferrin content is 200.0 mg.
It is beneficial when:
- allocryptopine content is 1.0 mg, z o - and nimodipine content is 20.0 zng, - and potassium iodide content is 120.0 mg, - and potassium iodate content is 30.0 mg, - and inuline content is 125.0 mg, - and silver content is 0.10 mg, - and zinc content is 10.0 mg, - and chromium content is 0.05 mg, - and orotic acid content is 250.0 mg, - and desferrin content is 100.0 mg.
It is beneficial when the weight ratio of allocryptopine to nimodipme to potassium iodide to potassium iodate to inuline to silver to zinc to chromium to orotic acid to desferrin is generally maintain as 1:20:120:30:125:0.1:10:0.05:250:100.
to The pharmaceutical mixture and method of making it may further comprise pharmaceutically effective amounts of taraxasterol and B-sitosterol. It is beneficial when the pharmaceutical mixture and method of making it is characterized by mixing, in the room temperature, of allocryptopine, in the amount from 1.0 mg to 10.0 mg; nimodipine, in the amount from 20.0 mg to 100.0 mg; potassium iodide, in the amount from 120.0 mg to 560.0 mg; potassium iodate, in the amount from 30.0 mg to 140.0 mg; inuline, in the amount from 125.0 mg to 375.0 mg; silver, in the amount from 0.10 mg to 0.50 mg; zinc, in the amount from 10.0 mg to 20.0 mg; chromium, in the amount from 0.05 mg to 0.20 mg; orotic acid, in the amount from 150.0 mg to 500.0 mg; desferrin, in the amount from 100.0 mg to 300.0 mg;
2o taraxasterol, in the amount from 250-400 mg, and 13-sitosterol in the amount from 300-500 mg until a mix approximating uniform substance is produced, subsequently pressed into tablets9 and can also have a form of coated tablets, or can be shaped into a wafer, a suppository, effervescent powder, gel, or colloid solution;
or made into suspension, syrup, salt soluble in body fluids, or liquid for intramuscular or IV injections, also in ampules.
It is beneficial when the weight ratio of allocryptopine to nimodipine to potassium iodide to potassium iodate to inuline to silver to zinc to chromium to orotic acid to desferrin to taraxasterol to B-sitosterol is generally maintain as 1:20:120:30:125:0.1:10:0.05:250:100:400:500.
It is also beneficial when the weight ratio of allocryptopine to nimodipine to potassium iodide to potassium iodate to inuline to silver to zinc to chromium to orotic acid to desferrin to taraxasterol to B-sitosterol is generally maintain as l0 1:20:120:30:125:0.1:10:0.05:250:100:350:400.
It is beneficial when the mixture of the ingredients has a form of a tablet, or coated tablet, or wafer, or suppository, or effervescent powder, or gel, or a colloid solution.
It is beneficial when the mixture of the ingredients has a form of 15 suspension, or syrup, or salt soluble in body fluids, or liquids for intramuscular or IV injections.
The beneficial effect of the pharmaceutical mixture in the invention is blocking the mechanism of attaching the gp 160 protein of the HIV virus capsule to the receptors of the CI24+ cells of the human immune system, as well as blocking 2o the intracellular processes related to the HIV-1 and HIV-2 virus replication.
E~~aaxaple l~To. 1. Content of the pharmaceutical mixture:
- allocryptopine in the amount of 10.0 mg, - nimodipine in the amount of 100.0 mg, - potassium iodide in the amount of 560.0 mg, - potassium iodate in the amount of 140.0 mg, - inuline in the amount of 375.0 mg, - silver in the amount of 0.50 mg, - zinc in the amount of 20.0 mg, - chromium in the amount of 0.20 mg, - orotic acid in the amount of 500.0 mg, - desferrin in the amount of 300.0 mg.
to Production of the pharmaceutical mixture:
Mix together in the room temperature: 10.0 mg of allocryptopine, 100.0 mg of nimodipine, 560.0 mg of potassium iodide, 140:0 mg of potassium iodate, 375.0 mg of inuline, 0.50 mg of silver, 20.0 mg of zinc, 0.20 mg of chromium, 500.0 mg of orotic acid, and 300.0 mg of desferrin.
After adding all ingredients, mix them all together for about 10-20 minutes until a uniform substance is produced. The mix can then be pressed into tablets, and can also have a form of coated tablets, or can be shaped into a wafer, a suppository, effervescent powder, gel, or colloid solution.
2 0 ~:~a~mpl~ I'~T~. 2. Content of the pharmaceutical mixture:
- allocryptopine in the amount of 1.0 mg, - nimodipine in the amount of 20.0 mg, - potassium iodide in the amount of 120.0 mg, - potassium iodate in the amount of 30.0 mg, - mulme in the amount of 125.0 mg, - silver in the amount of 0.10 mg, - zinc in the amount of 10.0 mg, - chromium in the amount of 0.05 mg, - orotic acid in the amount of 150.0 mg, - desferrin in the amount of 100.0 mg.
Production of the pharmaceutical mixture:
IvIix together in the room temperature: 1.0 mg of allocryptopine, 20.0 mg of 1 o nimodipinc, 120.0 mg of potassium iodide, 30.0 mg of potassium iodatc, 125.0 mg of inuline, 0. I O mg of silver, 10.0 mg of zinc, 0.05 mg of chromium, 150.0 mg of orotic acid, and 100.0 mg of desferrin.
After adding all ingredients, mix them all together for about 10-20 minutes until a uniform substance is produced.
The product can then be made into suspension, syrup, salt soluble in body fluids, or liquid fox intramuscular or TV injections, also in ampules.
Exaruple IV~. 3. Content of the pharmaceutical mixture:
- allocryptopine in the amount of 10.0 mg, 2 0 - nimodipine in the amount of 100.0 mg, - potassium iodide in the amount of 560.0 mg, - potassium iodate in the amount of 140.0 mg, - inulinc in the amount of 375.0 mg, - silver in the amount of 0.50 mg, - zinc in the amount of 20.0 mg, - chromium in the amount of 0.20 mg, - orotic acid in the amount of 500.0 mg, - desferrin in the amount of 300.0 mg, - taraxasterol in the amount of 400 mg, - B-sitosterol in the amount of 500 mg.
production of the pharmaceutical mixture:
Mix together in the room temperature: I0.0 mg of allocryptopine, 100.0 mg so of nimodipine, 560.0 mg of potassium iodide, 140.0 mg of potassium iodate, 375.0 mg of inuline, 0.50 mg of silver, 20.0 mg of zinc, 0.20 mg of chromium, 500.0 mg of orotic acid, 300.0 mg of desferrin, 400 mg of taraxasterol, and 500mg. of B-sitosterol.
After adding all ingredients, mix them all together for about 10-20 minutes until a uniform substance is produced. The mix can then be pressed into tablets, and can also have a form of coated tablets, or can be shaped into a wafer, a suppository, effervescent powder, gel, or colloid solution.
E~saxrapl~ N~. 4. Content of the pharmaceutical mixture:
- allocryptopine in the amount of 1.0 mg, - nimodipine in the amount of 20.0 mg, - potassium iodide in the amount of 120.0 mg, - potassium iodate in the amount of 30.0 mg, - mulme in the amount of 125.0 mg, - silver in the amount of 0.10 mg, - zinc in the amount of 10.0 mg, - chromium in the amount of O.OS mg, - orotic acid in the amount of 150.0 mg, - desferrin in the amount of 100.0 mg, - taraxasterol in the amount of 2S0 mg, - B-sitosterol in the amount of 300 mg.
1 o Production of the pharmaceutical mixture:
Mix together in the room temperature: 1.0 mg of allocryptopine, 20.0 mg of nimodipine, 120.0 mg of potassium iodide, 30.0 mg of potassium iodate, 125.0 mg of inuline, 0.10 mg of silver, 10.0 mg of zinc, O.OS mg of chromium, I 50.0 mg of orotic acid, 100.0 mg of desferrin, 250 mg of taraxasterol, and 300mg. of B-i5 sitosterol.
After adding all ingredients, mix them all together for about 10-20 minutes until a uniform substance is produced.
The product can then be made into suspension, syrup, salt soluble in body fluids, or liquid for intramuscular or IV injections, also in ampules.
~ o It should be understood that the term 'Gpharmaceutically effective amount"
means an effective amount of the pharmaceutical mixture of the present invention (comprising a mixture of allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid and desferrin). Actual dosage levels of the pharmaceutical composition of this invention can be varied so as to achieve the desired therapeutic response for a particular patient, compositions and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
The invented mixture has a particular application in treatment of the Acquired Immunodeficiency Syndrome, or AIDS.
Synopsis of the Description The subj ect of the invention is a pharmaceutical mixture for blocking the HIV-1 and HIV-2 virus replication in the GD4+ cells of the human immune system in that viral infection, and in All~S contains previously known carriers and/or auxiliary substances, as well as active substances, and it is characterized by the presence of at least 10 chemical substances as active substances, among them, allocryptopine, present in the amount from 1.0 mg to 10.0 mg; nimodipine, present to in the amount from 20.0 mg to 100.0 mg; potassium iodide, present in the amount from 120.0 mg to 560.0 mg; potassium iodate, present in the amount from 30.0 mg to 140.0 mg; inulina, present in the amount from 125.0 mg to 375.0 mg; silver, present in the amount from 0.10 mg to 0.50 mg; zinc, present in the amount from 10.0 mg to 20.0 mg; chromium, present in the amount from 0.05 mg to 0.20 mg;
orotic acid, present in the amount from 150.0 mg to 500.0 mg; desferrin, present in the amount from 100.0 mg to 300.0 mg Summary A pharmaceutical mixture and a method of its production of a therapeutic 2o composition for blocking the HIV-1 and HIV-2 virus replication in the CI~4~+ cells of the human immune system in all stages of that viral infection, and in .~IL2S for the treatment of HIV in a patient in need of such treatment, the therapeutic composition comprising of pharmaceutically effective amounts of allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid and desferrin. In one embodiment of the invention, the pharmaceutical mixture and method further comprises pharmaceutically effective amounts of taraxasterol and B-sitosterol.
Detailed Description of the Invention The invention pertains also to the method of production of the pharmaceutical mixture for blocking the HIV-1 and HIV-2 virus replication in the C1~4+ cells of the human immune system in all stages of that viral infection, and in to AIDS, characterized by mixing, in the room temperature, of allocryptopine, in the amount from 1.0 mg to 10.0 mg; nimodipine, in the amount from 20.0 mg to 100.0 mg; potassium iodide, in the amount from 120.0 mg to 560.0 mg; potassium iodate, in the amount from. 30.0 mg to 140.0 mg; inuline, in the amount from 125.0 mg to 375.0 mg; silver, in the amount from 0.10 mg to 0.50 mg; zinc, in the amount from is 10.0 mg to 20.0 mg; chromium, in the amount from 0.05 mg to 0.20 mg; orotic acid, in the amount from 150.0 mg to 500.0 mg; desferrin, in the amount from 100.0 mg to 300.0 mg, until a mix approximating uniform substance is produced, subsequently pressed into tablets, and can also have a form of coated tablets, or can be shaped into a wafer, a suppository, effervescent powder, gel, or colloid solution;
2 0 or made into suspension, syrup, salt soluble in body fluids, or liquid for intramuscular or I~ injections, also in ampules.
In the existing publications pertaining to treatment regimens for patients with a diagnosed HIV infection, or with the Acquired Imrnunodeficiency Syndrome (AIDS), there has been no description of any medications/ pharmaceutical preparations for blocking the HIV-1 and HIV-2 virus replication in the CD4+
cells of the human immune system based on the reasoning adopted here.
The premiss underlying the invention discussed here is the reasoning that the basis for the HIV- I and HIV-2 virus replication in the CD4+ cells of the human immune system is the exeitono-excimeric correlation between the HIV- I and HIV-2 viruses and the CD4 cell of the human immune system.
The effect of the adoption of that reasoning is as follows: the initiation of the therapy aimed at treatment of the HIV-1 and HIV-2 viral infections, and AIDS, to is reduced to delivering substances completely blocking the mechanism causing the HIV-1 and HIV-2 replication to the patient's body.
The following substances proved to be helpful in that task: allocryptopine, an alkaloid found in the Chelidonium maius plant, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid and desferrin.
Other 15 substances found to be helpful in this task were taraxasterol and B-sitosterol.
It is known that: allocryptopine is a nucleotide phosphodiesterase blocker, nimodipine is a calcium channel blocker, potassium iodide when combined with potassium iodate in the acidic environment, produces iodic free radicals, inuline is a polysaccharide which is not decomposed in the body9 silver, zinc, and chromium ~ o are elements playing a role in the enzymatic processes, - desferrin chelates ferric ions, - ~r~tic acid a the precursor of the nucleotide compounds.
However, the substances listed above have never appeared nor been applied together, and in particular they have not been used together in the therapeutic application such as those described in this invention.
The goal of the invention is supplying the pharmaceutical mixture for blocking the HIV-1 and HIV-2 virus replication in the CD4+ cells of the human immune system.
The invention provides that the pharmaceutical mixture for blocking the HIV-1 and HIV2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS, contains previously known carriers and/or auxiliary substances, as well as active substances, and it is characterized by the presence of at least 10 chemical substances as active substances, among them:
to - allocryptopine is present in the amount from 1.0 mg to 10.0 mg, - nimodipine is present in the amount from 20.0 mg to 100.0 mg, - potassium iodide is present in the amount from 120.0 mg to 560.0 mg, - potassium iodate is present in the amount from 30.0 mg to 140.0 mg, - inuline is present in the amount from 125.0 mg to 375.0 mg, 15 - silver is present in the amount from 0.10 mg to 0.50 mg, - zinc is present in the amount from 10.0 mg to 20.0 mg, -- chromium is present in the amount from 0.05 mg to 0.20 mg, - orotic acid is present in the amount from 150.0 mg to 500.0 mg, -desferrin is present in the amount from 100.0 mg to 300.0 mg ao It is beneficial v~hen:
- allocryptopine content is 10.0 mg, - and nimodipine content is 100.0 mg, - and potassium iodide content is 560.0 mg, - and potassium iodate content is 140.0 mg, - and inuline content is 375.0 mg, - and silver content is 0.50 mg, - and zinc content is 20.0 mg, - and chromium content is 0.20 mg, and orotic acid content is 500.0 mg, - and desferrin content is 300.0 mg.
It is beneficial when:
- allocryptopine content is 4.50 mg, - and nimodipine content is 60.0 mg, - and potassium iodide content is 340.0 mg, i5 - and potassium iodate content is X5.0 mg, - and inuline content is 250.0 mg, - and silver content is 0.30 mg, - and zinc content is 15.0 mg, - and chromium content is 0.125 mg, - and orotic acid content is 325.0 mg, - and desferrin content is 200.0 mg.
It is beneficial when:
_7_ - allocryptopine content is 4.50 mg, - and nimodipine content is 60.0 mg, - and potassium iodide content is 340.0 mg, - and potassium iodate content is 85.0 mg, - and inuline content is 250.0 mg, - and silver content is 0.30 mg, - and zinc content is 15.0 mg, - and chromium content is 0.125 mg, - and orotic acid content is 325.0 mg, to - and desferrin content is 200.0 mg, - and taraxasterol content is 350 mg, - and B-sitosterol content is 400 mg, It is beneficial when:
- allocryptopine content is 1.0 mg, - and nimodipine content is 20.0 mg, - and potassium iodide content is 120.0 mg, - and potassium iodate content is 30.0 mg, - and inulinc content is 125.0 mg, ~ o - and silver content is 0.10 mg, - arid zinc content is 10.0 mg, - and chromium content is 0.05 mg, - and orotic acid content is 250.0 mg, _g_ - and desferrin content is 100.0 mg, - and taraxasterol content is 250 mg, - and B-sitosterol content is 300 mg It is beneficial when:
- allocryptopine content is 1.0 mg, - and nimodipine content is 20.0 mg, - and potassium iodide content is 120.0 mg, - and potassium iodate content is 30.0 mg, to - and muline content is 125.0 mg, - and silver content is 0.10 mg, - and zinc content is 10.0 mg, - and chromium content is 0.05 mg, - and orotic acid content is 250.0 mg, - and desferrin content is 100.0 mg.
It is beneficial when the weight ratio of allocryptopine to nimodipine to potassium iodide to potassium iodate to inuline to silver to zinc to chromium to orotic acid to desferrin is generally maintained as 1:20:120:30:125:0.1:10:0.05:250:100.
~ o It is beneficial when the mixture of the ingredients has a form of a tablet, or coated tablet, or wafer, oi° suppository, or effervescent powder°, or gel, or colloid solution.
It is beneficial when the mixture of the ingredients has a form of suspension, or syrup, or salt soluble in body fluids, or liquids for intramuscular or IV injections.
The production of the pharmaceutical mixture for blocking the HIV-1 and HIV-2 virus replication in the CD4+ cells of the human immune system in all stages of that viral infection, and in AIDS, is characterized by mixing, in the room temperature, the following ingredients: - - allocryptopine in the amount from 1.0 ~, mg to 10.0 mg, - nimodipme in the amount from 20.0 mg to 100.0 mg, - potassium iodide in the amount from 120.0 mg to 560.0 mg, so - potassium iodatc in the amount from 30.0 mg to 140.0 mg, - incline in the amount from 125.0 mg to 375.0 mg, - silver in the amount from 0.10 mg to 0.50 mg, - zinc in the amount from 10.0 mg to 20.0 mg, - chromium in the amount from 0.05 mg to 0.20 mg, - orotic acid in the amount from 150.0 mg to 500.0 mg, -desferrin in the amount from 100.0 mg to 300.0 mg, until homogeneous mixture is created.
It is beneficial when:
2 0 - alloc~yptopine content is 10.0 mg, - and nimodipinc content is 100.0 mg, - and potassium iodide content is 560.0 mg, - and potassium iodate content is 140.0 mg, - and inuline content is 375.0 mg, - and silver content is 0.50 mg, - and zinc content is 20.0 mg, - and chromium content is 0.20 mg, - and orotic acid content is 500.0 mg, - and desferrin content is 300.0 mg.
It is beneficial when:
- allocryptopine content is 4.50 mg, - and nimodipine content is 60.0 mg, to - and potassium iodide content is 340.0 mg, - and potassium iodate content is 85.0 mg, - and inuline content is 250.0 mg, - and silver content is 0.30 mg, - and zinc content is 15.0 mg, - and chromium content is 0.125 mg, - and orotic acid content is 325.0 mg, - and desferrin content is 200.0 mg.
It is beneficial when:
- allocryptopine content is 1.0 mg, z o - and nimodipine content is 20.0 zng, - and potassium iodide content is 120.0 mg, - and potassium iodate content is 30.0 mg, - and inuline content is 125.0 mg, - and silver content is 0.10 mg, - and zinc content is 10.0 mg, - and chromium content is 0.05 mg, - and orotic acid content is 250.0 mg, - and desferrin content is 100.0 mg.
It is beneficial when the weight ratio of allocryptopine to nimodipme to potassium iodide to potassium iodate to inuline to silver to zinc to chromium to orotic acid to desferrin is generally maintain as 1:20:120:30:125:0.1:10:0.05:250:100.
to The pharmaceutical mixture and method of making it may further comprise pharmaceutically effective amounts of taraxasterol and B-sitosterol. It is beneficial when the pharmaceutical mixture and method of making it is characterized by mixing, in the room temperature, of allocryptopine, in the amount from 1.0 mg to 10.0 mg; nimodipine, in the amount from 20.0 mg to 100.0 mg; potassium iodide, in the amount from 120.0 mg to 560.0 mg; potassium iodate, in the amount from 30.0 mg to 140.0 mg; inuline, in the amount from 125.0 mg to 375.0 mg; silver, in the amount from 0.10 mg to 0.50 mg; zinc, in the amount from 10.0 mg to 20.0 mg; chromium, in the amount from 0.05 mg to 0.20 mg; orotic acid, in the amount from 150.0 mg to 500.0 mg; desferrin, in the amount from 100.0 mg to 300.0 mg;
2o taraxasterol, in the amount from 250-400 mg, and 13-sitosterol in the amount from 300-500 mg until a mix approximating uniform substance is produced, subsequently pressed into tablets9 and can also have a form of coated tablets, or can be shaped into a wafer, a suppository, effervescent powder, gel, or colloid solution;
or made into suspension, syrup, salt soluble in body fluids, or liquid for intramuscular or IV injections, also in ampules.
It is beneficial when the weight ratio of allocryptopine to nimodipine to potassium iodide to potassium iodate to inuline to silver to zinc to chromium to orotic acid to desferrin to taraxasterol to B-sitosterol is generally maintain as 1:20:120:30:125:0.1:10:0.05:250:100:400:500.
It is also beneficial when the weight ratio of allocryptopine to nimodipine to potassium iodide to potassium iodate to inuline to silver to zinc to chromium to orotic acid to desferrin to taraxasterol to B-sitosterol is generally maintain as l0 1:20:120:30:125:0.1:10:0.05:250:100:350:400.
It is beneficial when the mixture of the ingredients has a form of a tablet, or coated tablet, or wafer, or suppository, or effervescent powder, or gel, or a colloid solution.
It is beneficial when the mixture of the ingredients has a form of 15 suspension, or syrup, or salt soluble in body fluids, or liquids for intramuscular or IV injections.
The beneficial effect of the pharmaceutical mixture in the invention is blocking the mechanism of attaching the gp 160 protein of the HIV virus capsule to the receptors of the CI24+ cells of the human immune system, as well as blocking 2o the intracellular processes related to the HIV-1 and HIV-2 virus replication.
E~~aaxaple l~To. 1. Content of the pharmaceutical mixture:
- allocryptopine in the amount of 10.0 mg, - nimodipine in the amount of 100.0 mg, - potassium iodide in the amount of 560.0 mg, - potassium iodate in the amount of 140.0 mg, - inuline in the amount of 375.0 mg, - silver in the amount of 0.50 mg, - zinc in the amount of 20.0 mg, - chromium in the amount of 0.20 mg, - orotic acid in the amount of 500.0 mg, - desferrin in the amount of 300.0 mg.
to Production of the pharmaceutical mixture:
Mix together in the room temperature: 10.0 mg of allocryptopine, 100.0 mg of nimodipine, 560.0 mg of potassium iodide, 140:0 mg of potassium iodate, 375.0 mg of inuline, 0.50 mg of silver, 20.0 mg of zinc, 0.20 mg of chromium, 500.0 mg of orotic acid, and 300.0 mg of desferrin.
After adding all ingredients, mix them all together for about 10-20 minutes until a uniform substance is produced. The mix can then be pressed into tablets, and can also have a form of coated tablets, or can be shaped into a wafer, a suppository, effervescent powder, gel, or colloid solution.
2 0 ~:~a~mpl~ I'~T~. 2. Content of the pharmaceutical mixture:
- allocryptopine in the amount of 1.0 mg, - nimodipine in the amount of 20.0 mg, - potassium iodide in the amount of 120.0 mg, - potassium iodate in the amount of 30.0 mg, - mulme in the amount of 125.0 mg, - silver in the amount of 0.10 mg, - zinc in the amount of 10.0 mg, - chromium in the amount of 0.05 mg, - orotic acid in the amount of 150.0 mg, - desferrin in the amount of 100.0 mg.
Production of the pharmaceutical mixture:
IvIix together in the room temperature: 1.0 mg of allocryptopine, 20.0 mg of 1 o nimodipinc, 120.0 mg of potassium iodide, 30.0 mg of potassium iodatc, 125.0 mg of inuline, 0. I O mg of silver, 10.0 mg of zinc, 0.05 mg of chromium, 150.0 mg of orotic acid, and 100.0 mg of desferrin.
After adding all ingredients, mix them all together for about 10-20 minutes until a uniform substance is produced.
The product can then be made into suspension, syrup, salt soluble in body fluids, or liquid fox intramuscular or TV injections, also in ampules.
Exaruple IV~. 3. Content of the pharmaceutical mixture:
- allocryptopine in the amount of 10.0 mg, 2 0 - nimodipine in the amount of 100.0 mg, - potassium iodide in the amount of 560.0 mg, - potassium iodate in the amount of 140.0 mg, - inulinc in the amount of 375.0 mg, - silver in the amount of 0.50 mg, - zinc in the amount of 20.0 mg, - chromium in the amount of 0.20 mg, - orotic acid in the amount of 500.0 mg, - desferrin in the amount of 300.0 mg, - taraxasterol in the amount of 400 mg, - B-sitosterol in the amount of 500 mg.
production of the pharmaceutical mixture:
Mix together in the room temperature: I0.0 mg of allocryptopine, 100.0 mg so of nimodipine, 560.0 mg of potassium iodide, 140.0 mg of potassium iodate, 375.0 mg of inuline, 0.50 mg of silver, 20.0 mg of zinc, 0.20 mg of chromium, 500.0 mg of orotic acid, 300.0 mg of desferrin, 400 mg of taraxasterol, and 500mg. of B-sitosterol.
After adding all ingredients, mix them all together for about 10-20 minutes until a uniform substance is produced. The mix can then be pressed into tablets, and can also have a form of coated tablets, or can be shaped into a wafer, a suppository, effervescent powder, gel, or colloid solution.
E~saxrapl~ N~. 4. Content of the pharmaceutical mixture:
- allocryptopine in the amount of 1.0 mg, - nimodipine in the amount of 20.0 mg, - potassium iodide in the amount of 120.0 mg, - potassium iodate in the amount of 30.0 mg, - mulme in the amount of 125.0 mg, - silver in the amount of 0.10 mg, - zinc in the amount of 10.0 mg, - chromium in the amount of O.OS mg, - orotic acid in the amount of 150.0 mg, - desferrin in the amount of 100.0 mg, - taraxasterol in the amount of 2S0 mg, - B-sitosterol in the amount of 300 mg.
1 o Production of the pharmaceutical mixture:
Mix together in the room temperature: 1.0 mg of allocryptopine, 20.0 mg of nimodipine, 120.0 mg of potassium iodide, 30.0 mg of potassium iodate, 125.0 mg of inuline, 0.10 mg of silver, 10.0 mg of zinc, O.OS mg of chromium, I 50.0 mg of orotic acid, 100.0 mg of desferrin, 250 mg of taraxasterol, and 300mg. of B-i5 sitosterol.
After adding all ingredients, mix them all together for about 10-20 minutes until a uniform substance is produced.
The product can then be made into suspension, syrup, salt soluble in body fluids, or liquid for intramuscular or IV injections, also in ampules.
~ o It should be understood that the term 'Gpharmaceutically effective amount"
means an effective amount of the pharmaceutical mixture of the present invention (comprising a mixture of allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid and desferrin). Actual dosage levels of the pharmaceutical composition of this invention can be varied so as to achieve the desired therapeutic response for a particular patient, compositions and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
Claims (31)
1. A therapeutic composition for the treatment of HIV in a patient in need of such treatment, the therapeutic composition comprising of pharmaceutically effective amounts of allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid and desferrin.
2. The therapeutic composition of claim 1, wherein the allocryptopine is present in the amount from about 1.0 mg to about 10.0 mg, nimodipine is present in the amount from about 20.0 mg to about 100.0 mg, potassium iodide is present in the amount from about 120.0 mg to about 560.0 mg, potassium iodate is present in the amount from about 30.0 mg to about 140.0 mg, inuline is present in the amount from about 125.0 mg to about 375.0 mg, silver is present in the amount from about 0.10 mg to about 0.50 mg, zinc, present in the amount from 10.0 mg to about 20.0 mg, chromium is present in the amount from about 0.05 mg to about 0.20 mg, orotic acid is present in the amount from about 150.0 mg to about 500.0 mg, and the desferrin is present in the amount from about 100.0 mg to about 300.0 mg.
3. The therapeutic composition of claim 1, wherein the allocryptopine is present in the amount of about 10.0 mg, the nimodipine is present in the amount of about 100.0 mg, the potassium iodide is present in the amount of about 560.0 mg, the potassium iodate is present in the amount of about 140.0 mg, the inuline is present in the amount of about 375.0 mg, the silver is present in the amount of about 0.50 mg, the zinc is present in the amount of about 20.0 mg, the chromium is present in the amount of about 0.20 mg, the orotic acid is present in the amount of about 500.0 mg, and the desferrin is present in the amount of about 300.0 mg.
4. The therapeutic composition of claim 1, wherein the allocryptopine is present in the amount of about 4.5 mg, the nimodipine is present in the amount of about 60.0 mg, the potassium iodide is present in the amount of about 340.0 mg, the potassium iodate is present in the amount of about 85.0 mg, the inuline is present in the amount of about 250.0 mg, the silver is present in the amount of about 0.30 mg, the zinc is present in the amount of about 15.0 mg, the chromium is present in the amount of about 0.125 mg, the orotic acid is present in the amount of about 325.0 mg, and the desferrin is present in the amount of about 200.0 mg.
5. The therapeutic composition of claim 1, wherein the allocryptopine is present in the amount of about 1.0 mg, the nimodipine is present in the amount of about 20.0 mg, the potassium iodide is present in the amount of about 120.0 mg, the potassium iodate is present in the amount of about 30.0 mg, the inuline is present in the amount of about 125.0 mg, the silver is present in the amount of about 0.10 mg, the zinc is present in the amount of about 10.0 mg, the chromium is present in the amount of about 0.05 mg, the orotic acid is present in the amount of about 250.0 mg, and the desferrin is present in the amount of about 100.0 mg.
6. The therapeutic composition of claim 1 further comprises a weight ratio of allocryptopine to nimodipine to potassium iodide to potassium iodate to inuline to silver to zinc to chromium to orotic acid to desferrin of about 1:20:120:30:125:0.1:10:0.05:250:100, respectively.
7. The therapeutic composition of claim 1, wherein said composition is in a form suitable for administering to a patient, wherein the form is selected from the group consisting of a tablet, coated tablet, wafer, suppository, effervescent powder, gel, and a colloid suspension.
8. A therapeutic composition for the treatment of HIV in a patient in need of such treatment, the therapeutic composition comprising of pharmaceutically effective amounts of allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid, desferrin, taraxasterol and B-sitosterol.
9. The therapeutic composition of claim 8, wherein the allocryptopine is present in the amount from about 1.0 mg to about 10.0 mg, nimodipine is present in the amount from about 20.0 mg to about 100.0 mg, potassium iodide is present in the amount from about 120.0 mg to about 560.0 mg, potassium iodate is present in the amount from about 30.0 mg to about 140.0 mg, inuline is present in the amount from about 125.0 mg to about 375.0 mg, silver is present in the amount from about 0.10 mg to about 0.50 mg, zinc, present in the amount from 10.0 mg to about 20.0 mg, chromium is present in the amount from about 0.05 mg to about 0.20 mg, orotic acid is present in the amount from about 150.0 mg to about 500.0 mg, the desferrin is present in the amount from about 100.0 mg to about 300.0 mg, the taraxasterol is present in the amount from about 250mg to about 400 mg, and the B-sitosterol is present in the amount from about 300 mg to about 500 mg.
10. The therapeutic composition of claim 8, wherein the allocryptopine is present in the amount of about 10.0 mg, the nimodipine is present in the amount of about 100.0 mg, the potassium iodide is present in the amount of about 560.0 mg, the potassium iodate is present in the amount of about 140.0 mg, the incline is present in the amount of about 375.0 mg, the silver is present in the amount of about 0.50 mg, the zinc is present in the amount of about 20.0 mg, the chromium is present in the amount of about 0.20 mg, the orotic acid is present in the amount of about 500.0 mg, the desferrin is present in the amount of about 300.0 mg, the taraxasterol is present in the amount of about 400 mg, and the B-sitosterol is present in the amount of about 500 mg.
11. The therapeutic composition of claim 8, wherein the allocryptopine is present in the amount of about 4.5 mg, the nimodipine is present in the amount of about 60.0 mg, the potassium iodide is present in the amount of about 340.0 mg, the potassium iodate is present in the amount of about 85.0 mg, the incline is present in the amount of about 250.0 mg, the silver is present in the amount of about 0.30 mg, the zinc is present in the amount of about 15.0 mg, the chromium is present in the amount of about 0.125 mg, the orotic acid is present in the amount of about 325.0 mg, the desferrin is present in the amount of about 200.0 mg, the taraxasterol is present in the amount of about 350 mg, and the B-sitosterol is present in the amount of about 400 mg.
12. The therapeutic composition of claim 8, wherein the allocryptopine is present in the amount of about 1.0 mg, the nimodipine is present in the amount of about 20.0 mg, the potassium iodide is present in the amount of about 120.0 mg, the potassium iodate is present in the amount of about 30.0 mg, the inuline is present in the amount of about 125.0 mg, the silver is present in the amount of about 0.10 mg, the zinc is present in the amount of about 10.0 mg, the chromium is present in the amount of about 0.05 mg, the orotic acid is present in the amount of about 250.0 mg, the desferrin is present in the amount of about 100.0 mg, the taraxasterol is present in the amount of about 250 mg, and the B-sitosterol is present in the amount of about 300 mg.
13. A method of preparing a pharmaceutical mixture for blocking HIV
virus replication, comprising the step of mixing together pharmaceutically effective amounts of allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid, and desferrin to provide the pharmaceutical mixture for blocking HIV-1 and HIV-2 virus replication.
virus replication, comprising the step of mixing together pharmaceutically effective amounts of allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid, and desferrin to provide the pharmaceutical mixture for blocking HIV-1 and HIV-2 virus replication.
14. The method of claim 13, wherein the step of mixing is performed at room temperature.
15. The method of claim 13, wherein the allocryptopine is present in the amount from about 1.0 mg to about 10.0 mg, nimodipine is present in the amount from about 20.0 mg to about 100.0 mg, potassium iodide is present in the amount from about 120.0 mg to about 560.0 mg, potassium iodate is present in the amount from about 30.0 mg to about 140.0 mg, inuline is present in the amount from about 125.0 mg to about 375.0 mg, silver is present in the amount from about 0.10 mg to about 0.50 mg, zinc, present in the amount from 10.0 mg to about 20.0 mg, chromium is present in the amount from about 0.005 mg to about 0.20 mg, orotic acid is present in the amount from about 150.0 mg to about 500.0 mg, and the desferrin is present in the amount from about 100.0 mg to about 300.0 mg.
16. The method of claim 13, wherein the allocryptopine is present in the amount of about 10.0 mg, the nimodipine is present in the amount of about 100.0 mg, the potassium iodide is present in the amount of about 560.0 mg, the potassium iodate is present in the amount of about 140.0 mg, the inuline is present in the amount of about 375.0 mg, the silver is present in the amount of about 0.50 mg, the zinc is present in the amount of about 20.0 mg, the chromium is present in the amount of about 0.20 mg, the orotic acid is present in the amount of about 500.0 mg, and the desferrin is present in the amount of about 300.0 mg.
17. The method of claim 13, wherein the allocryptopine is present in the amount of about 4.5 mg, the nimodipine is present in the amount of about 60.0 mg, the potassium iodide is present in the amount of about 340.0 mg, the potassium iodate is present in the amount of about 85.0 mg, the inuline is present in the amount of about 250.0 mg, the silver is present in the amount of about 0.30 mg, the zinc is present in the amount of about 15.0 mg, the chromium is present in the amount of about 0.125 mg, the orotic acid is present in the amount of about 325.0 mg, and the desferrin is present in the amount of about 200.0 mg.
18. The method of claim 13, wherein the allocryptopine is present in the amount of about 1.0 mg, the nimodipine is present in the amount of about 20.0 mg, the potassium iodide is present in the amount of about 120.0 mg, the potassium iodate is present in the amount of about 30.0 mg, the inuline is present in the amount of about 125.0 mg, the silver is present in the amount of about 0.10 mg, the zinc is present in the amount of about 10.0 mg, the chromium is present in the amount of about 0.05 mg, the orotic acid is present in the amount of about 250.0 mg, and the desferrin is present in the amount of about 100.0 mg.
19. The method of claim 13, wherein the pharmaceutical mixture comprises a weight ratio of allocryptopine to nimodipine to potassium iodide to potassium iodate to inuline to silver to zinc to chromium to orotic acid to desferrin of about 1:20:120:30:125:0.1:10:0.05:250:100, respectively.
20. The method of claim 13 further comprising converting the pharmaceutical mixture into a form suitable for administering to a patient, wherein the form is selected from the group consisting of a tablet, coated tablet, wafer, suppository, effervescent powder, gel, and a colloid.
21. A method of treating a HIV infection, the method comprising administering to a patient in need of such treatment a pharmaceutical mixture comprising of pharmaceutically effective amounts of allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid and desferrin.
22. The method of claim 21, wherein the pharmaceutical mixture is administered intramuscularly.
23. The method of claim 21, wherein the pharmaceutical mixture is administered by intravenous injection.
24. A method of preparing a pharmaceutical mixture for blocking HIV
virus replication, comprising the step of mixing together pharmaceutically effective amounts of allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid, desferrin, taraxasterol, and B-sitosterol to provide the pharmaceutical mixture for blocking HIV-1 and HIV-2 virus replication.
virus replication, comprising the step of mixing together pharmaceutically effective amounts of allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid, desferrin, taraxasterol, and B-sitosterol to provide the pharmaceutical mixture for blocking HIV-1 and HIV-2 virus replication.
25. The method of claim 24, wherein the step of mixing is performed at room temperature.
26. The method of claim 24, wherein the allocryptopine is present in the amount from about 1.0 mg to about 10.0 mg, nimodipine is present in the amount from about 20.0 mg to about 100.0 mg, potassium iodide is present in the amount from about 120.0 mg to about 560.0 mg, potassium iodate is present in the amount from about 30.0 mg to about 140.0 mg, inuline is present in the amount from about 125.0 mg to about 375.0 mg, silver is present in the amount from about 0.10 mg to about 0.50 mg, zinc, present in the amount from 10.0 mg to about 20.0 mg, chromium is present in the amount from about 0.05 mg to about 0.20 mg, orotic acid is present in the amount from about 150.0 mg to about 500.0 mg, the desferrin is present in the amount from about 100.0 mg to about 300.0 mg, the taraxasterol is present in the amount from about 250mg to about 400 mg, and the B-sitosterol is present in the amount from about 300 mg to about 500 mg.
27. The method of claim 24, wherein the pharmaceutical mixture comprises a weight ratio of allocryptopine to nimodipine to potassium iodide to potassium iodate to inuline to silver to zinc to chromium to orotic acid to desferrin to taraxasterol to B-sitosterol of about 1:20:120:30:125:0.1:10:0.05:250:100:250:300, respectively.
28. The method of claim 24 further comprising converting the pharmaceutical mixture into a foam suitable for administering to a patient, wherein the form is selected from the group consisting of a tablet, coated tablet, wafer, suppository, effervescent powder, gel, and a colloid.
29. A method of treating a HIV infection, the method comprising administering to a patient in need of such treatment a pharmaceutical mixture comprising of pharmaceutically effective amounts of allocryptopine, nimodipine, potassium iodide, potassium iodate, inuline, silver, zinc, chromium, orotic acid, desferrin, taraxasterol, and B-sitosterol.
30. The method of claim 29, wherein the pharmaceutical mixture is administered intramuscularly.
31. The method of claim 29, wherein the pharmaceutical mixture is administered by intravenous injection.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/353,483 | 2003-01-29 | ||
| US10/353,483 US20030203045A1 (en) | 2002-04-30 | 2003-01-29 | Therapeutic composition for the treatment of HIV-1 and HIV-2 |
| PCT/US2004/002536 WO2004066954A2 (en) | 2003-01-29 | 2004-01-29 | A therapeutic composition for the treatment of hiv-1 and hiv-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2514252A1 true CA2514252A1 (en) | 2004-08-12 |
Family
ID=32823743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002514252A Abandoned CA2514252A1 (en) | 2003-01-29 | 2004-01-29 | A therapeutic composition for the treatment of hiv-1 and hiv-2 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1589961A4 (en) |
| JP (1) | JP2006516633A (en) |
| KR (1) | KR20050094461A (en) |
| CN (1) | CN1747726A (en) |
| AU (1) | AU2004206996A1 (en) |
| CA (1) | CA2514252A1 (en) |
| RU (1) | RU2005123957A (en) |
| WO (1) | WO2004066954A2 (en) |
| ZA (1) | ZA200505977B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810625B (en) * | 2010-04-09 | 2012-05-23 | 上海新康制药厂 | Application of taraxasterol |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970212A (en) * | 1982-05-18 | 1990-11-13 | Nowicky Wassili | Method of treating human illnesses which compromise the ability to mount an effective immunological response |
| CA1337047C (en) * | 1988-08-18 | 1995-09-19 | Peter Dodd Cooper | Gamma inulin compositions |
| WO1990011761A1 (en) * | 1989-03-31 | 1990-10-18 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| US5977073A (en) * | 1991-06-06 | 1999-11-02 | Life Sciences' Technologies, Inc. | Nutrient composition for treatment of immune disorders |
| RU2107502C1 (en) * | 1997-03-27 | 1998-03-27 | Открытое акционерное общество "Ветеринарные препараты" | Iodine monochloride, veterinary preparation possessing wide range of action |
| AU4944500A (en) * | 1999-06-29 | 2001-01-31 | Robert H. Jacobs | A method for optimizing immune activity in the treatment of auto-immune diseases and chronic immune conditions |
| RU2195277C2 (en) * | 2001-02-09 | 2002-12-27 | Третьяков Василий Васильевич | Method of treatment of hiv-infection |
| GB2374008B (en) * | 2001-04-04 | 2005-03-16 | John Carter | Pharmaceutical compositions comprising copper and zinc |
| PL353693A1 (en) * | 2002-04-30 | 2003-11-03 | Bogusław Jeleń | Compound pharmaceutical for inhibiting replication of hiv-1 and hiv-2 viruses in the cd4+ cells of human immunological system at all stages of infection and in the aids syndrome as well as method of manufacture of compound pharmaceutical for inhibiting replication of hiv-1 and hiv-2 viruses in the cd+ cells of human immunological system at all stages of infection and in the aids syndrome |
-
2004
- 2004-01-29 JP JP2006503151A patent/JP2006516633A/en active Pending
- 2004-01-29 EP EP04706521A patent/EP1589961A4/en not_active Withdrawn
- 2004-01-29 RU RU2005123957/15A patent/RU2005123957A/en not_active Application Discontinuation
- 2004-01-29 AU AU2004206996A patent/AU2004206996A1/en not_active Abandoned
- 2004-01-29 WO PCT/US2004/002536 patent/WO2004066954A2/en not_active Application Discontinuation
- 2004-01-29 KR KR1020057013692A patent/KR20050094461A/en not_active Application Discontinuation
- 2004-01-29 CN CNA2004800039434A patent/CN1747726A/en active Pending
- 2004-01-29 CA CA002514252A patent/CA2514252A1/en not_active Abandoned
-
2005
- 2005-07-26 ZA ZA200505977A patent/ZA200505977B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050094461A (en) | 2005-09-27 |
| ZA200505977B (en) | 2006-05-31 |
| EP1589961A4 (en) | 2006-02-15 |
| EP1589961A2 (en) | 2005-11-02 |
| JP2006516633A (en) | 2006-07-06 |
| RU2005123957A (en) | 2006-01-27 |
| CN1747726A (en) | 2006-03-15 |
| AU2004206996A1 (en) | 2004-08-12 |
| WO2004066954A3 (en) | 2005-03-17 |
| WO2004066954A2 (en) | 2004-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA015560B1 (en) | Method of treating viral hepatitis | |
| JP2015510818A (en) | Silk reservoir for drug delivery | |
| JP2009522371A5 (en) | ||
| RU2007101695A (en) | MEDICINAL PRODUCT FOR TREATMENT OF DIABETES MELLITUS BASED ON EXENATIDE AND DALARGIN, APPLICATION AND METHOD OF TREATMENT | |
| WO2010126818A1 (en) | Intranasal delivery system for dantrolene | |
| Harfouch et al. | Therapeutic approaches for COVID 19: Challenges and successes | |
| US5491150A (en) | Supplementary therpeutic agents for the treatment of immunodeficiency syndrome | |
| WO2018005914A1 (en) | Regimens and compositions for treating hiv infections and aids | |
| US20230193219A1 (en) | Superoxide dismutase compositions and methods | |
| JPS63166832A (en) | Solution for nose | |
| CA2514252A1 (en) | A therapeutic composition for the treatment of hiv-1 and hiv-2 | |
| US20030203045A1 (en) | Therapeutic composition for the treatment of HIV-1 and HIV-2 | |
| US5432187A (en) | Benzimidazole anthelmintic in the treatment of microsporidial infections | |
| CA3157656A1 (en) | Use of nicotinamide mononucleotide (nmn) for the prevention and/or treatment of rheumatoid arthritis, and corresponding compositions | |
| BE644613A (en) | ||
| JPH0415766B2 (en) | ||
| JP2003527414A (en) | Drugs for treating hepatitis C | |
| US20230295585A1 (en) | Superoxide dismutase compositions and methods | |
| JPS6330284B2 (en) | ||
| CN117017986A (en) | Application of cotinamide in preparing anti-tuberculosis drugs | |
| JP2688733B2 (en) | Agent for preventing and treating gastrointestinal mucosal disorders | |
| WO2021222835A1 (en) | Compositions and methods comprising stable reduced glutathione | |
| WO2021105461A1 (en) | Use of compounds for the prevention and/or treatment of ankylosing spondylitis, and corresponding compositions | |
| REDDY'S | FDA Drug Approvals | |
| Antonelli et al. | MACROPHAGE PROTECTION BY NUCLEOSIDE AND NUCLEOTIDE ANALOGUE ADMINISTRATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |